Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04768101 · ClinicalTrials.gov registry record · Early Phase 1
Quantitative Imaging of Brain Glymphatic Function in Humans
A Early Phase 1 study of Parkinson Disease, sponsored by Vanderbilt University Medical Center.
- Active
- Registry status
- Early Phase 1
- Development phase
- 140
- Enrollment target
- 1
- Study location
NCT04768101: Active Early Phase 1 study of Parkinson Disease, sponsored by Vanderbilt University Medical Center.
NCT04768101 is a Early Phase 1 study of Parkinson Disease that is active but no longer recruiting, run by Vanderbilt University Medical Center. The registered enrollment target is 140 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04768101, a Early Phase 1 study of Parkinson Disease, is active but no longer recruiting, sponsored by Vanderbilt University Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 140 participants
- Enrollment target
- 1
- Study location
Study Summary
Recent immunological and physiological studies have provided evidence in support of a central nervous system (CNS) lymphatic drainage system in vertebrate animals, and preliminary evidence has suggested that a similar system exists in humans. If operative, this system may have central relevance to many vascular and fluid clearance disorders such as stroke, multiple sclerosis, Parkinson's disease, and Alzheimer's disease related dementia (ADRD): diseases which represent some of the most pressing healthcare challenges of the 21st century. Evaluating this possibility will require improved, robust imaging methods sensitive to lymphatic drainage dysfunction; as such, the goal of this work is to apply novel magnetic resonance imaging approaches, optimized already for evaluating lymphatic circulation in patients with peripheral lymphatic dysfunction, to quantify relationships between physiological hallmarks of ADRD and CNS lymphatic function in humans.
Primary Outcome
Using a 3T MRI (body coil transmission and SENSE phased-array 32-channel reception), images will be taken. For analysis, a unitless ratio of diffusion along perivascular space relative to orthogonal to perivascular space at the level of the lateral brain ventricles will be calculated
Conditions Studied
Interventions
- DRUG [11C]-PIB
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2020-04-15 |
| Est. Completion | 2025-12-31 |
| Phase | Early Phase 1 |
What the registry record for NCT04768101 still lists
NCT04768101 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 1 intervention - of which [11C]-PIB is the first listed.
NCT04768101 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT04768101 about?
NCT04768101 is a clinical study titled "Quantitative Imaging of Brain Glymphatic Function in Humans". Recent immunological and physiological studies have provided evidence in support of a central nervous system (CNS) lymphatic drainage system in vertebrate animals, and preliminary evidence has suggested that a similar system exists in humans. If operative, this system may have central relevance to m...
What is the current status of trial NCT04768101?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 140 participants. The study started on 2020-04-15. Estimated completion is 2025-12-31.
What conditions does trial NCT04768101 study?
This clinical trial studies the following conditions: Parkinson Disease.
What interventions are being tested in trial NCT04768101?
The interventions under investigation include: [11C]-PIB (DRUG).
Who is sponsoring clinical trial NCT04768101?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04768101 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04768101's enrollment target sits among peer trials
140 57th of 297 higher than 239 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients
RECRUITING · Early Phase 1
-
Title: A Multimodal Exercise Program With Gamification for Parkinson Disease (MEP+G)
RECRUITING · Early Phase 1
-
Multiple Objective Particle Swarm Optimization Postural Instability Gait Disorder
RECRUITING · Early Phase 1
-
Noise-augmented Automatic Speech Recognition for Speech Treatment in Parkinson's Disease
RECRUITING · Early Phase 1
-
Longitudinal TSPO PET Imaging With [18F]DPA-714 in PPMI (PPMI DPA-714 PET Imaging)
RECRUITING · Early Phase 1
-
Evaluation of Neuroinflammation in Parkinson's Disease Using 18F-NOS PET/CT
ACTIVE NOT RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI